[en] BACKGROUND & AIMS: Psoriasiform and eczematiform lesions are associated with anti-tumor necrosis factor (TNF)-alpha therapies. We assessed clinical characteristics, risk factors, and outcomes of skin disease in patients with inflammatory bowel diseases that presented with psoriasiform and eczematiform lesions induced by anti-TNF-alpha agents. METHODS: We studied 85 patients (69 with Crohn's disease, 15 with ulcerative colitis, and 1 with indeterminate colitis; 62 women) with inflammatory skin lesions (62 psoriasiform and 23 eczematiform lesions). RESULTS: Twenty-four patients had a history of inflammatory skin lesions and 15 had a familial history of inflammatory skin disease. Locations of eczematiform lesions varied whereas scalp and flexural varieties were mostly psoriasiform. Skin lesions emerged but inflammatory bowel disease was quiescent in 69 patients following treatment with any type of anti-TNF-alpha agent (60 with infliximab, 20 with adalimumab, and 5 with certolizumab). Topical therapy resulted in partial or total remission in 41 patients. Patients with psoriasiform lesions that were resistant to topical therapy and that changed anti-TNF-alpha therapies once or twice developed recurring lesions. Overall, uncontrolled skin lesions caused 29 patients to stop taking TNF-alpha inhibitors. CONCLUSIONS: Inflammatory skin lesions following therapy with TNF-alpha inhibitors occurred most frequently among women and patients with a personal or familial history of inflammatory skin disease; lesions did not correlate with intestinal disease activity. Recurring and intense skin lesions caused 34% of patients in this study to discontinue use of anti-TNF-alpha agents.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Rahier, Jean*-Francois
Buche, Sebastien
Peyrin-Biroulet, Laurent
Bouhnik, Yoram
Duclos, Bernard
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the accent I randomised trial. Lancet 2002, 359:1541-1549.
Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007, 357:239-250.
Sands B.E., Blank M.A., Diamond R.H., et al. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the Accent II study. Aliment Pharmacol Ther 2006, 23:1127-1136.
Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
Peyrin-Biroulet L., Deltenre P., de Suray N., et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6:644-653.
Toruner M., Loftus E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
Siegel C.A., Marden S.M., Persing S.M., et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7:874-881.
Ko J.M., Gottlieb A.B., Kerbleski J.F. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat 2009, 20:100-108.
Smith C.H., Anstey A.V., Barker J.N., et al. British association of dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009, 161:987-1019.
Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19:210-216.
Flendrie M., Vissers W.H., Creemers M.C., et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005, 7:R666-R676.
Lee H.H., Song I.H., Friedrich M., et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007, 156:486-491.
Harrison M.J., Dixon W.G., Watson K.D., et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009, 68:209-215.
Delaporte E. [Immune-mediated inflammatory diseases and psoriasis]. Ann Dermatol Venereol 2008, 135(Suppl 4):S269-S274.
Fidder H., Schnitzler F., Ferrante M., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
Esmailzadeh A., Yousefi P., Farhi D., et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatol Basel Switzerland 2009, 219:263-267.
Wollina U., Hansel G., Koch A., et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008, 9:1-14.
Whitacre C.C. Sex differences in autoimmune disease. Nat Immunol 2001, 2:777-780.
Zandman-Goddard G., Peeva E., Shoenfeld Y. Gender and autoimmunity. Autoimmun Rev 2007, 6:366-372.
Ho P., Bruce I.N., Silman A., et al. Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum 2005, 52:3596-3602.
Hagforsen E., Awder M., Lefvert A.K., et al. Palmoplantar pustulosis: an autoimmune disease precipitated by smoking?. Acta Derm Venereol 2002, 82:341-346.
Naldi L., Mercuri S.R. Smoking and psoriasis: from epidemiology to pathomechanisms. J Invest Dermatol 2009, 129:2741-2743.
Vissers W.H., Roelofzen J., De Jong E.M., et al. Flexural versus plaque lesions in psoriasis: an immunohistochemical differentiation. Eur J Dermatol 2005, 15:13-17.
Avila Alvarez A., García-Alonso L., Solar Boga A., et al. Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease [in Spanish]. An Pediatr (Barc) 2009, 70:278-281.
Peramiquel L., Puig L., Dalmau J., et al. Onset of flexural psoriasis during infliximab treatment for Crohn's disease. Clin Exp Dermatol 2005, 30:713-714.
Collamer A.N., Guerrero K.T., Henning J.S., et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008, 59:996-1001.
Mease P. TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004, 63:755-758.
Gottlieb A.B., Evans R., Li S., et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004, 51:534-542.
Papp K.A., Tyring S., Lahfa M., et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005, 152:1304-1312.
Palucka A.K., Blanck J.P., Bennett L., et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 2005, 102:3372-3377.
Nestle F.O., Conrad C., Tun-Kyi A., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005, 202:135-143.
de Gannes G.C., Ghoreishi M., Pope J., et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007, 143:223-231.
Seneschal J., Milpied B., Vergier B., et al. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 2009, 161:1081-1088.
